MannKind Corp (MNKD)

Currency in USD
3.800
-0.150(-3.80%)
Closed·
3.810+0.010(+0.26%)
·
Advertisement
MNKD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.7054.010
52 wk Range
2.2306.510
Key Statistics
Prev. Close
3.8
Open
4.01
Day's Range
3.705-4.01
52 wk Range
2.23-6.51
Volume
4.61M
Average Volume (3m)
4.52M
1-Year Change
-34.0278%
Book Value / Share
-0.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MNKD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
7.969
Upside
+109.70%
Members' Sentiments
Bearish
Bullish
ProTips
Not profitable over the last twelve months

MannKind Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Analyst Ratings

7 Buy
1 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 7.969
(+109.70% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy8.00+110.53%-Maintain11/09/2026
H.C. Wainwright
Buy10.00+163.16%-Maintain06/08/2026
Wells Fargo
Buy13.00+242.11%14.00Maintain06/08/2026
Wells Fargo
Buy14.00+268.42%11.00Maintain30/07/2026
H.C. Wainwright
Buy10.00+163.16%-Maintain30/07/2026

MannKind Corp Earnings Call Summary for Q2/2026

  • MannKind Q2 revenue hit $109.4M, up 43% YoY and beating estimates; EPS of -$0.01 matched forecasts despite GAAP net loss widening to $19M.
  • Marketed products revenue surged 111% YoY; Afrezza pediatric launch and FUROSCIX ReadyFlow approval drove growth with $17M and $22.2M sales respectively.
  • Company maintained FUROSCIX full-year guidance of $110M-$120M; expects H2 strength from seasonal patterns and improved patient affordability.
  • R&D and SG&A expenses jumped 31% and 84% respectively as firm invests in launches; $45M CVR payment and $16M related charge due in Q3.
  • Stock rose 4.55% to $4.14 in regular trading but fell 3.45% after-hours as investors weighed strong revenue momentum against rising costs.
Last Updated: 05/08/2026, 22:44
Read Full Transcript

Earnings

Latest Release
05/08/2026
EPS / Forecast
-0.01 / -0.01
Revenue / Forecast
109.37M / 109.02M
EPS Revisions
Last 90 days

Compare MNKD to Peers and Sector

Metrics to compare
MNKD
Peers
Sector
Relationship
P/E Ratio
−28.0x−0.9x−0.3x
PEG Ratio
0.11−0.030.00
Price/Book
−18.2x3.3x2.6x
Price / LTM Sales
3.1x4.3x3.0x
Upside (Analyst Target)
109.7%364.1%58.6%
Fair Value Upside
Unlock23.3%8.4%Unlock

MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. The company’s commercial products include Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes; Furoscix, a formulation of furosemide injection to treat edema in pediatric patients and adult patients with chronic heart failure or chronic kidney disease; and V-Go, a mechanical basal-bolus insulin delivery system, which provides continuous subcutaneous infusion of insulin in adults that require insulin. It also developed Tyvaso DPI inhalation powder for the treatment of pulmonary arterial hypertension, as well as for the treatment of pulmonary hypertension associated with interstitial lung disease. The company’s pipeline of treatments for orphan lung diseases include MNKD-201, a dry-powder formulation of nintedanib for the treatment of idiopathic pulmonary fibrosis and MNKD-701 that focuses on bumetanide. It has collaboration and license agreement with United Therapeutics Corporation; collaboration agreement with Thirona Bio, Inc. to evaluate the therapeutic for the treatment of pulmonary fibrosis; and licensing and collaboration agreement with Rose Pharma Inc. to develop ROSE-010 Technosphere for weight management. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
76.23M23.71%297.28M
Other Institutional Investors
110.36M34.32%430.40M
Public Companies & Retail Investors
134.95M41.97%526.32M
Total
321.54M100.00%1.25B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.99%32,133,223125,320
Rubric Capital Management LP5.60%18,000,00070,200

People Also Watch

0.522
HUMA
+3.78%
126.21
EWBC
+0.95%
1.2000
GERN
-0.83%
19.40
VRDN
+2.16%
47.150
RIGL
+0.38%

FAQ

What Is the MannKind (NASDAQ: MNKD) Share Price Today?

The MannKind stock price today is 3.800 USD.

What Stock Exchange Does MannKind (MNKD) Trade On?

MannKind is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for MannKind?

The stock symbol (also called a 'ticker') for MannKind is "MNKD."

What Is the Current MannKind Market Capitalisation?

As of today, MannKind (NASDAQ: MNKD) market cap is 1.270B USD.

What Is MannKind's (MNKD) Earnings Per Share (TTM)?

The MannKind EPS is currently -0.158 (Trailing Twelve Months).

When Is the Next MannKind Earnings Date?

MannKind's next earnings report will be released on 10/11/2026.

Is MNKD a Buy or Sell From a Technical Analyst Perspective?

Based on today's MannKind moving averages and other technical indicators, the daily buy/sell signal for MNKD stock is Strong Buy.

How Many Times Has MannKind Stock Split?

MannKind has split 1 times. (See the MNKD stock split history page for full effective split date and price information.)

How Many Employees Does MannKind Have?

MannKind has 592 employees, based on their latest Companies House report.

What is the current trading status of MannKind (NASDAQ: MNKD)?

As of 03/10/2026, MannKind (MNKD) is trading at a share price of 3.800 USD, with a previous close of 3.800 USD. The stock has fluctuated within a day range of 3.705 USD to 4.010 USD, while its 52-week range spans from 2.230 USD to 6.510 USD.

What Is MannKind (MNKD) Price Target According to Analysts?

The average 12-month price target for MannKind is 7.969 USD, with a high estimate of 13 USD and a low estimate of 4.75 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +109.70% Upside potential.

What Is the MNKD Premarket Price?

MNKD's last pre-market stock price is 3.990 USD. The pre-market share volume is 10,500.000, and the stock has decreased by 0.040, or 1.010%.

What Is the MNKD After Hours Price?

MNKD's last after hours stock price is 3.810 USD, the stock has decreased by 0.010, or 0.260%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.